Dr. George on Results of Abi Race Trial in Prostate Cancer

Daniel J. George, MD
Published: Saturday, Jun 02, 2018



Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the results of the prospective multicenter Abi Race trial, which compared outcomes of African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) and prednisone. George shared this insight in an interview with OncLive during the 2018 ASCO Annual Meeting.

In prostate cancer in America, African-American men are not only at higher risk for developing prostate cancer, they are also are at high risk for prostate cancer mortality, George explains. This is 2.5 times more likely than it is for Caucasian patients, and a 5 times greater likelihood than Asian-American patients. Researchers suggest there is a genetic component to this, he adds.

In the international COUGAR-AA-302 trial, African-American men were underrepresented; there were 28 African-American patients out of an overall 1100 patients, George says. However, in 15 of the 28 African-American patients who received abiraterone, there were greater and longer response rates by prostate-specific antigen (PSA) compared with the overall population.

In a retrospective, nested, case-control study, researchers from Duke Cancer Institute found this similar pattern with a higher PSA response rate and a longer time to PSA progression in the African-American versus Caucasian patients, demonstrating that African Americans may have greater and more durable responses to abiraterone/prednisone than Caucasian patients.

<<< 2018 ASCO Annual Meeting


Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the results of the prospective multicenter Abi Race trial, which compared outcomes of African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) and prednisone. George shared this insight in an interview with OncLive during the 2018 ASCO Annual Meeting.

In prostate cancer in America, African-American men are not only at higher risk for developing prostate cancer, they are also are at high risk for prostate cancer mortality, George explains. This is 2.5 times more likely than it is for Caucasian patients, and a 5 times greater likelihood than Asian-American patients. Researchers suggest there is a genetic component to this, he adds.

In the international COUGAR-AA-302 trial, African-American men were underrepresented; there were 28 African-American patients out of an overall 1100 patients, George says. However, in 15 of the 28 African-American patients who received abiraterone, there were greater and longer response rates by prostate-specific antigen (PSA) compared with the overall population.

In a retrospective, nested, case-control study, researchers from Duke Cancer Institute found this similar pattern with a higher PSA response rate and a longer time to PSA progression in the African-American versus Caucasian patients, demonstrating that African Americans may have greater and more durable responses to abiraterone/prednisone than Caucasian patients.

<<< 2018 ASCO Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x